ARCHIVES

FDA Rile Changes Reporting Requirements for Adverse Events

This article is from The Cancer Letter archive.

Vol. 20 No. 44 | November 18, 1994

Download PDF Visit The Full Archive

Related Articles

Clinical Trials: “Master Protocol” To Rely On Biomarkers In Testing Multiple Lung Cancer Agents

November 15, 2013

White Heads NIH Legislative Policy Office

March 5, 2010

Clinical Trials: NCI Removes Brooklyn Site From PLCO Trials

October 24, 1997

Recision, 1981 Budget Threats Hangover NCI

March 14, 1980

Correction: Appropriations Reports Included Language of Minorities and Underserved

October 15, 1999

Psychiatric Disorders Often Overlooked By Oncologists

September 28, 2007